摘要 In advanced-stage prostate cancer, bone metastases are often incurable and cause chronic pain, bone fractures, and decreased quality of life. Researchers have previously identified that transforming growth factor-b (TGF-b) signaling is an important regulator of bone metastases in prostate cancer and that targeting TGF-b signaling is a promising therapeutic strategy [1,2].
Abstract: In advanced-stage prostate cancer, bone metastases are often incurable and cause chronic pain, bone fractures, and decreased quality of life. Researchers have previously identified that transforming growth factor-b (TGF-b) signaling is an important regulator of bone metastases in prostate cancer and that targeting TGF-b signaling is a promising therapeutic strategy [1,2].
Alexandra M. Blee, Haojie Huang. PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis[J]. Asian Journal of Urology, 2016, 3(1): 1-3.
Alexandra M. Blee, Haojie Huang. PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis. Asian Journal of Urology, 2016, 3(1): 1-3.
Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen Y, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther 2012; 23:871-82.
[2]
Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, et al. Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone 2012;50:695-703.
[3]
Fournier PG, Juarez P, Jiang G, Clines GA, Niewolna M, Kim HS, et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 2015;27: 809-21.
[4]
Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013;13: 788-99.
[5]
Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, et al. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell 2010;37:123-34.
[6]
Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63: 4299-304.
[7]
Tang LY, Yamashita M, Coussens NP, Tang Y, Wang X, Li C, et al. Ablation of Smurf2 reveals an inhibition in TGF-beta signalling through multiple mono-ubiquitination of Smad3. EMBO J 2011; 30:4777-89.
[8]
Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, et al. Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics 2014;9:918-27.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
